Fig 5.

In vivo short-term efficacy of VSV-ΔM51-GFP against KCM tumors. (A) MUC1.Tg male mice, 16 to 18 weeks old, were subcutaneously (s.q.) injected with KCM cells in the right flank (n = 30). Tumors were established by day 5, and the mice were randomly divided into 5 groups (n = 6 per group). On day 5, mice were administered one dose of gemcitabine or PBS i.p. On day 7, treatments began with groups being administered 10⁸ CIU VSV-ΔM51-GFP, UV-killed VSV-ΔM51-GFP, or PBS three times, on days 7, 9, and 11. Tumor size was monitored by caliper measurements, and tumor weight was calculated according to the standard ellipsoid formula: weight in grams = (length in cm × width²)/2. Mice were sacrificed at day 18 p.t.i. Bonferroni post hoc tests compared all groups to PBS and VSV-ΔM51-GFP to VSV-ΔM51-GFP + gemcitabine (*, P < 0.05; **, P < 0.01; ***, P < 0.001; ##, P < 0.01). (B) At the endpoint (as indicated in panel A), tumor sections from each group were homogenized, and RNA was extracted from the supernatant. RNA was reverse transcribed, and the resulting cDNA was PCR amplified using the primers that bind part of the intergenic region on either side of the VSV M gene. PCR was conducted for 35 or 40 cycles, and samples were electrophoresed on a 2% agarose gel stained with ethidium bromide.